News
CERS
1.850
+3.35%
0.060
Weekly Report: what happened at CERS last week (0429-0503)?
Weekly Report · 2d ago
Cerus’s Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy Rating
TD Cowen analyst Josh Jennings has maintained their bullish stance on CERS stock, giving a Buy rating on May 3. Cerus has a strong start to the year with a 24% growth in product revenue for the first quarter. The company is nearing complete adoption of their INTERCEPT technology in Canada.
TipRanks · 3d ago
Cerus Price Target Raised to $4.00/Share From $3.00 by Cantor Fitzgerald
Dow Jones · 4d ago
Cerus Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 4d ago
Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
Benzinga · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Joint (JYNT) and Cerus (CERS)
TipRanks · 5d ago
Cerus Corporation: Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 5d ago
CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024
Cerus reported earnings per share of -5 cents for the first quarter of 2024. The company reported revenue of $38.37 million. This was 6.75% worse than the analyst estimate of $41.14 million. Cerus also reported results for the fourth quarter of 2015.
Investorplace · 5d ago
*Cerus On Track to Post Double-Digit Pdt Rev Growth This Yr >CERS
Dow Jones · 5d ago
*Cerus Committed to Adjusted EBITDA Breakeven for FY24
Dow Jones · 5d ago
*Cerus Expects to Report a GAAP Loss Attributable to Co for FY24
Dow Jones · 5d ago
*Cerus Backs FY Product Rev Guidance Range of $172 M to $175 M >CERS
Dow Jones · 5d ago
CERUS OUTLOOK FY REVENUE USD 172-175 MILLION
Reuters · 5d ago
CERUS CORP - REITERATING ITS FULL-YEAR 2024 ANNUAL PRODUCT REVENUE GUIDANCE
Reuters · 5d ago
*Cerus 1Q Loss $9.69M >CERS
Dow Jones · 5d ago
Press Release: Cerus Corporation Announces First Quarter 2024 Financial Results
Cerus Corporation Announces First Quarter 2024 Financial Results First Quarter Product Revenue Increased 24% from Prior Year Quarter. U.S. ReCePI Phase 3 clinical trial for INTERCEPT Blood System for Red Blood Cells successfully met primary endpoint. The Company is reiterating its full-year 2024 annual product revenue guidance of $172 million.
Dow Jones · 5d ago
Press Release: Cerus Corporation Announces First -3-
Three months ended March 31, 2014, the US is the largest market for platelet kits in the world. North America accounts for 44% of the total number of kits sold. The US is also the largest region for the number of patients treated with the kits. Sales of the kits in North America have grown by 44% in the past year.
Dow Jones · 5d ago
Weekly Report: what happened at CERS last week (0422-0426)?
Weekly Report · 04/29 11:49
Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), MiMedx Group (MDXG)
TipRanks · 04/26 12:50
Weekly Report: what happened at CERS last week (0415-0419)?
Weekly Report · 04/22 11:37
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.